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Dear editor: We thank Namendys and
colleagues for their comments and
would like to respond here. We do not
concur with their statement that
sildenafil should not be administered
to patients with ARDS and would like
to elucidate our point of view. We are
under the impression that Namendys
and coworkers feel that the results
may have been different if only
patients meeting the current definition
of pulmonary artery hypertension had
been included [1]. We need to
emphasize that the study we recently
reported on in this journal [2] was
performed in patients meeting the
NAECC criteria for ARDS [3], but
not necessarily meeting the criteria of
pulmonary arterial hypertension
(PAH) [1]. In only five out of the ten
patients, MPAP was [25 mmHg,
PAOP was B15 mmHg, and PVR was
[3 Wood units (240 dyne 9 s/cm5).
Our hypothesis was that by selec-
tively reducing the pulmonary
vascular tone in ARDS by means of
sildenafil, the shunt fraction would
decrease, and oxygenation would
thereby improve. This hypothesis,
however, was only in part supported
by our results: pulmonary vascular
tone decreased; oxygenation and
shunt fraction did not improve.
An important cause for these findings
may have been sepsis. NO-mediated
systemic (and pulmonary) vasodila-
tion may have been enhanced by
sildenafil as an intrinsic consequence
of its mode of action. Due to the
pronounced drop in systemic blood
pressure, preferential vasodilation
was not reached, explaining the
deterioration in oxygenation and
shunt fraction. Sepsis, or other
inflammatory conditions requiring
vasopressive support, frequently
coincide with ARDS, thereby poten-
tially rendering the treatment of
pulmonary hypertension more
complicated in patients suffering
from ARDS as compared to
ambulatory patients. However, in a
recent study assessing the hemody-
namic and gas exchange effects of
sildenafil in patients with chronic
obstructive pulmonary disease and
pulmonary hypertension, the effects
of sildenafil were much alike [4].
Sildenafil improved pulmonary
hemodynamics at rest and during
exercise, but also decreased systemic
arterial blood pressure and led to a
deterioration of arterial oxygenation,
which was ascribed to inhibition of
hypoxic pulmonary vasoconstriction.
The improvement in exercise capacity
of sildenafil in ambulatory patients
with PAH may be primarily the con-
sequence of hemodynamic and not of
ventilatory effects [5]. In ARDS, it
remains to be questioned whether
therapy should be targeted on oxy-
genation, since levels of PaO2 have
not been associated with adverse
outcome in ARDS. The beneficial
effect of sildenafil on right ventricular
performance may be of additional
value besides other strategies
(e.g., ventilation in prone position) in
patients with severe PAH who do not
have arterial hypotension.
Namendys and colleagues further
suggest that the approved dosage of
sildenafil in PAH is 20 mg three
times daily, and the 50 mg adminis-
tered as a single dose in our study
may have been too much. Yet, in
ambulatory patients with COPD and
PAH, there was no significant differ-
ence in hemodynamic effects between
a 20- and 40-mg dose [4].
Finally, we emphasize our study
was designed as a ‘‘proof of concept
study’’ and to obtain physiologic
information. It was underpowered to
make a statement on the effect of
sildenafil on the outcome in patients
suffering from ARDS. Therefore,
until a large, sufficiently powered and
well-designed trial determines this
effect, sildenafil should be considered
potentially useful in selected patients
with stable hemodynamics and life-
threatening ARDS.
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